The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

Primary IOL implantation in pediatric open globe injuries with active inflammation showed inferior visual outcomes compared ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

Corneal refractive surgery has been performed on millions of patients to decrease their spectacle dependence. Most of these patients have high expectations of visual function—but as these patients age ...

Cataract surgery remains one of the most frequently performed and successful surgical procedures worldwide, involving the removal of a clouded natural lens and its replacement with an intraocular lens ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...

Billing practices with respect to premium intraocular lenses (“IOLs”) implanted in surgery centers can create various risks for the surgery center. These risks arise when a physician supplies the ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...